Literature DB >> 34495748

X-Linked Agammaglobulinemia and COVID-19: Two Case Reports and Review of Literature.

Fiji Madona Devassikutty1, Abhinav Jain2,3, Athulya Edavazhippurath4, Michael Chittettu Joseph5, Mohammed Manakkattu Thekke Peedikayil6, Vinod Scaria2,3, Pulukool Sandhya7, Geeta Madathil Govindaraj1.   

Abstract

Introduction: The Centers for Disease Control and Prevention (CDC) has listed primary immunodeficiency disorders as being predisposed to severe coronavirus disease 2019 (COVID-19). However, patients affected with X-linked agammaglobulinemia (XLA) have shown contrary results. In this study, we present 2 boys in late adolescence from south India with XLA who were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as a review of cases reported in the literature. Case Presentation: Two patients with XLA had been diagnosed late and were started on regular immunoglobulin prophylaxis only during adolescence. Both of them had developed bronchiectasis, an irreversible suppurative lung disease. However, both patients made an uneventful recovery without the need for artificial ventilation or convalescent plasma.
Conclusion: Successful outcomes of patients with XLA and COVID-19, except for delayed recovery, from our experience and from global reports are intriguing and the role of B cell depletion is being studied as well. Further research and clinical experience are necessary to fully elucidate the reasons for these observations.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; X-linked agammaglobulinemia; primary immunodeficiency

Mesh:

Year:  2021        PMID: 34495748      PMCID: PMC8664121          DOI: 10.1089/ped.2021.0002

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol Pulmonol        ISSN: 2151-321X            Impact factor:   0.885


  10 in total

1.  Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

Authors:  Mark Roschewski; Michail S Lionakis; Jeff P Sharman; Joseph Roswarski; Andre Goy; M Andrew Monticelli; Michael Roshon; Stephen H Wrzesinski; Jigar V Desai; Marissa A Zarakas; Jacob Collen; Keith Rose; Ahmed Hamdy; Raquel Izumi; George W Wright; Kevin K Chung; Jose Baselga; Louis M Staudt; Wyndham H Wilson
Journal:  Sci Immunol       Date:  2020-06-05

2.  Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma.

Authors:  Haoli Jin; James C Reed; Sean T H Liu; Hsi-En Ho; Joao Pedro Lopes; Nicole B Ramsey; Omar Waqar; Farah Rahman; Judith A Aberg; Nicole M Bouvier; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2020-09-15

3.  Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City.

Authors:  Hsi-En Ho; Sheryl Mathew; Michael J Peluso; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10-08

4.  Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.

Authors:  Estefanía Mira; Oscar A Yarce; Consuelo Ortega; Silvia Fernández; Natalia M Pascual; Cristina Gómez; Miguel A Alvarez; Ignacio J Molina; Rafael Lama; Manuel Santamaria
Journal:  J Allergy Clin Immunol Pract       Date:  2020-07-08

5.  Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor?

Authors:  Fateme Babaha; Nima Rezaei
Journal:  Am J Med Sci       Date:  2020-07-29       Impact factor: 2.378

6.  Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.

Authors:  Annarosa Soresina; Daniele Moratto; Marco Chiarini; Ciro Paolillo; Giulia Baresi; Emanuele Focà; Michela Bezzi; Barbara Baronio; Mauro Giacomelli; Raffaele Badolato
Journal:  Pediatr Allergy Immunol       Date:  2020-05-19       Impact factor: 5.464

7.  A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia.

Authors:  Isabella Quinti; Vassilios Lougaris; Cinzia Milito; Francesco Cinetto; Antonio Pecoraro; Ivano Mezzaroma; Claudio Maria Mastroianni; Ombretta Turriziani; Maria Pia Bondioni; Matteo Filippini; Annarosa Soresina; Giuseppe Spadaro; Carlo Agostini; Rita Carsetti; Alessandro Plebani
Journal:  J Allergy Clin Immunol       Date:  2020-04-22       Impact factor: 10.793

8.  SARS-CoV-2 positive virus culture 7 weeks after onset of COVID-19 in an immunocompromised patient suffering from X chromosome-linked agammaglobulinemia.

Authors:  Katharina Guetl; Florentine Moazedi-Fuerst; Konrad Rosskopf; Marianne Brodmann; Robert Krause; Philipp Eller; Patricia Wilhelmer; Florian Eisner; Nazanin Sareban; Peter Schlenke; Harald H Kessler; Ivo Steinmetz; Monika Redlberger-Fritz; Karin Stiasny; Martin Stradner
Journal:  J Infect       Date:  2020-10-27       Impact factor: 6.072

9.  COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience.

Authors:  Adrian M Shields; Siobhan O Burns; Sinisa Savic; Alex G Richter
Journal:  J Allergy Clin Immunol       Date:  2020-12-15       Impact factor: 14.290

10.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Authors:  Paul Bastard; Lindsey B Rosen; Qian Zhang; Eleftherios Michailidis; Hans-Heinrich Hoffmann; Yu Zhang; Karim Dorgham; Quentin Philippot; Jérémie Rosain; Vivien Béziat; Steven M Holland; Guy Gorochov; Emmanuelle Jouanguy; Charles M Rice; Aurélie Cobat; Luigi D Notarangelo; Laurent Abel; Helen C Su; Jean-Laurent Casanova; Jérémy Manry; Elana Shaw; Liis Haljasmägi; Pärt Peterson; Lazaro Lorenzo; Lucy Bizien; Sophie Trouillet-Assant; Kerry Dobbs; Adriana Almeida de Jesus; Alexandre Belot; Anne Kallaste; Emilie Catherinot; Yacine Tandjaoui-Lambiotte; Jeremie Le Pen; Gaspard Kerner; Benedetta Bigio; Yoann Seeleuthner; Rui Yang; Alexandre Bolze; András N Spaan; Ottavia M Delmonte; Michael S Abers; Alessandro Aiuti; Giorgio Casari; Vito Lampasona; Lorenzo Piemonti; Fabio Ciceri; Kaya Bilguvar; Richard P Lifton; Marc Vasse; David M Smadja; Mélanie Migaud; Jérome Hadjadj; Benjamin Terrier; Darragh Duffy; Lluis Quintana-Murci; Diederik van de Beek; Lucie Roussel; Donald C Vinh; Stuart G Tangye; Filomeen Haerynck; David Dalmau; Javier Martinez-Picado; Petter Brodin; Michel C Nussenzweig; Stéphanie Boisson-Dupuis; Carlos Rodríguez-Gallego; Guillaume Vogt; Trine H Mogensen; Andrew J Oler; Jingwen Gu; Peter D Burbelo; Jeffrey I Cohen; Andrea Biondi; Laura Rachele Bettini; Mariella D'Angio; Paolo Bonfanti; Patrick Rossignol; Julien Mayaux; Frédéric Rieux-Laucat; Eystein S Husebye; Francesca Fusco; Matilde Valeria Ursini; Luisa Imberti; Alessandra Sottini; Simone Paghera; Eugenia Quiros-Roldan; Camillo Rossi; Riccardo Castagnoli; Daniela Montagna; Amelia Licari; Gian Luigi Marseglia; Xavier Duval; Jade Ghosn; John S Tsang; Raphaela Goldbach-Mansky; Kai Kisand; Michail S Lionakis; Anne Puel; Shen-Ying Zhang
Journal:  Science       Date:  2020-09-24       Impact factor: 63.714

  10 in total
  3 in total

Review 1.  Associations and Disease-Disease Interactions of COVID-19 with Congenital and Genetic Disorders: A Comprehensive Review.

Authors:  Altijana Hromić-Jahjefendić; Debmalya Barh; Cecília Horta Ramalho Pinto; Lucas Gabriel Rodrigues Gomes; Jéssica Lígia Picanço Machado; Oladapo Olawale Afolabi; Sandeep Tiwari; Alaa A A Aljabali; Murtaza M Tambuwala; Ángel Serrano-Aroca; Elrashdy M Redwan; Vladimir N Uversky; Kenneth Lundstrom
Journal:  Viruses       Date:  2022-04-27       Impact factor: 5.818

2.  SARS-CoV-2 Infection in an Adolescent With X-linked Agammaglobulinemia.

Authors:  Noella Maria Delia Pereira; Paul T Heath; Katja Doerholt; Andres Fernando Almario-Hernandez; Clare Gilmour; Simon B Drysdale
Journal:  Pediatr Infect Dis J       Date:  2021-12-01       Impact factor: 3.806

Review 3.  COVID-19 and Inborn Errors of Immunity.

Authors:  Ottavia M Delmonte; Riccardo Castagnoli; Luigi D Notarangelo
Journal:  Physiology (Bethesda)       Date:  2022-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.